Product Name :
Allo-aca
Description:
Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models.
CAS:
Molecular Weight:
1074.19
Formula:
C48H75N13O15
Chemical Name:
(6S, 9S, 12S, 15S, 18S, 21S, 24S)-1-amino-6-((4-(2-amino-2-oxoethyl)-2-oxo-2H-chromen-7-yl)carbamoyl)-24-((2S, 3R)-2-amino-3-hydroxybutanamido)-9-(hydroxymethyl)-1-imino-12-isobutyl-18-isopropyl-15-methyl-8, 11, 14, 17, 20, 23-hexaoxo-21-propyl-2, 7, 10, 13, 16, 19, 22-heptaazaheptacosan-27-oic acid
Smiles :
CCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1=CC2OC(=O)C=C(CC(N)=O)C=2C=C1
InChiKey:
HBIZXCPYXWQUEB-JPBZROOYSA-N
InChi :
InChI=1S/C48H75N13O15/c1-8-10-29(56-42(70)31(14-15-36(65)66)58-46(74)38(50)25(7)63)43(71)61-39(23(4)5)47(75)54-24(6)40(68)59-32(17-22(2)3)44(72)60-33(21-62)45(73)57-30(11-9-16-53-48(51)52)41(69)55-27-12-13-28-26(18-35(49)64)19-37(67)76-34(28)20-27/h12-13,19-20,22-25,29-33,38-39,62-63H,8-11,14-18,21,50H2,1-7H3,(H2,49,64)(H,54,75)(H,55,69)(H,56,70)(H,57,73)(H,58,74)(H,59,68)(H,60,72)(H,61,71)(H,65,66)(H4,51,52,53)/t24-,25+,29-,30-,31-,32-,33-,38-,39-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{SKI II} medchemexpress|{SKI II} Apoptosis|{SKI II} Biological Activity|{SKI II} In Vivo|{SKI II} custom synthesis|{SKI II} Cancer}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models.|Product information|Molecular Weight: 1074.19|Formula: C48H75N13O15|Chemical Name: (6S, 9S, 12S, 15S, 18S, 21S, 24S)-1-amino-6-((4-(2-amino-2-oxoethyl)-2-oxo-2H-chromen-7-yl)carbamoyl)-24-((2S, 3R)-2-amino-3-hydroxybutanamido)-9-(hydroxymethyl)-1-imino-12-isobutyl-18-isopropyl-15-methyl-8, 11, 14, 17, 20, 23-hexaoxo-21-propyl-2, 7, 10, 13, 16, 19, 22-heptaazaheptacosan-27-oic acid|Smiles: CCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1=CC2OC(=O)C=C(CC(N)=O)C=2C=C1|InChiKey: HBIZXCPYXWQUEB-JPBZROOYSA-N|InChi: InChI=1S/C48H75N13O15/c1-8-10-29(56-42(70)31(14-15-36(65)66)58-46(74)38(50)25(7)63)43(71)61-39(23(4)5)47(75)54-24(6)40(68)59-32(17-22(2)3)44(72)60-33(21-62)45(73)57-30(11-9-16-53-48(51)52)41(69)55-27-12-13-28-26(18-35(49)64)19-37(67)76-34(28)20-27/h12-13,19-20,22-25,29-33,38-39,62-63H,8-11,14-18,21,50H2,1-7H3,(H2,49,64)(H,54,75)(H,55,69)(H,56,70)(H,57,73)(H,58,74)(H,59,68)(H,60,72)(H,61,71)(H,65,66)(H4,51,52,53)/t24-,25+,29-,30-,31-,32-,33-,38-,39-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Insulin degludec} MedChemExpress|{Insulin degludec} Insulin Receptor|{Insulin degludec} Purity & Documentation|{Insulin degludec} Data Sheet|{Insulin degludec} supplier|{Insulin degludec} Cancer} |Shelf Life: ≥12 months if stored properly.PMID:24458656 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Allo-aca inhibits leptin-induced proliferation of MDA-MB-231 cells at 50 pM concentration. Allo-aca inhibits leptin-induced proliferation of MCF-7 cells with an IC50 of 200 pM. Allo-aca at 250 nmol/L reduces VEGF-dependent leptin mRNA expression in both cell lines below base levels. Allo-aca inhibits VEGF mitogenic effects. Allo-aca inhibits VEGF-induced chemotaxis and chemokinesis in RF/6A retinal endothelial cells.|In Vivo:|In an MDA-MB-231 orthotopic mouse xenograft model, Allo-aca administered subcutaneously significantly extends the average survival time from 15.4 days (untreated controls) to 24 and 28.1 days at 0.1 and 1mg/kg/day doses, respectively.|Products are for research use only. Not for human use.|